Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.
Company profile
Ticker
SRRA
Exchange
Website
CEO
Stephen Dilly
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ProNAi Therapeutics Inc
SEC CIK
Corporate docs
Subsidiaries
Sierra Oncology Canada ULC ...
SRRA stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
11 Jul 22
EFFECT
Notice of effectiveness
8 Jul 22
EFFECT
Notice of effectiveness
8 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
POS AM
Prospectus update (post-effective amendment)
1 Jul 22
POS AM
Prospectus update (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Jul 22
Transcripts
Latest ownership filings
SC 13G/A
Rock Springs Capital Management LP
14 Feb 23
SC 13G/A
Versor Investments LP
10 Feb 23
SC 13D/A
Abingworth LLP
11 Jul 22
SC 13G/A
Vivo Capital IX, LLC
5 Jul 22
4
Change in insider ownership
1 Jul 22
4
Change in insider ownership
1 Jul 22
4
Mona Ashiya
1 Jul 22
4
Gaurav Aggarwal
1 Jul 22
4
Andrew Sinclair
1 Jul 22
4
Barbara Klencke
1 Jul 22
Financial summary
| Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 274.32 mm | 274.32 mm | 274.32 mm | 274.32 mm | 274.32 mm | 274.32 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 9.31 mm | 8.56 mm | 8.58 mm | 7.31 mm |
| Cash used (since last report) | n/a | n/a | 165.07 mm | 151.76 mm | 152.04 mm | 129.58 mm |
| Cash remaining | n/a | n/a | 109.25 mm | 122.55 mm | 122.27 mm | 144.73 mm |
| Runway (months of cash) | n/a | n/a | 11.7 | 14.3 | 14.3 | 19.8 |
Institutional ownership, Q1 2023
86.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 7 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 501.99 mm |
| Total shares | 21.03 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| GILD Gilead Sciences | 14.51 mm | $315.35 mm |
| Frazier Life Sciences Public Fund | 1.79 mm | $60.06 mm |
| Longitude Capital Partners III | 1.48 mm | $80.50 mm |
| Frazier Life Sciences VIII | 1.06 mm | $23.09 mm |
| Venrock Healthcare Capital Partners II | 984.75 k | $0.00 |
| New Leaf Biopharma Opportunities I | 661.90 k | $14.39 mm |
| Mangrove Partners Master Fund | 548.87 k | $8.60 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Jul 22 | Christy J. Oliger | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 17.7575 | 18,000 | 319.64 k | 0 |
| 1 Jul 22 | Georgia Erbez | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 17.7575 | 18,000 | 319.64 k | 0 |
| 1 Jul 22 | Kevin Norrett | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 31.54 | 35,000 | 1.10 mm | 0 |
| 1 Jul 22 | Kevin Norrett | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 16.73 | 11,700 | 195.74 k | 0 |
| 1 Jul 22 | Kevin Norrett | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 12.15 | 49,000 | 595.35 k | 0 |
| 1 Jul 22 | Kevin Norrett | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 12.05 | 100,000 | 1.21 mm | 0 |
| 1 Jul 22 | William D. Turner | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 31.54 | 35,000 | 1.10 mm | 0 |
| 1 Jul 22 | William D. Turner | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 16.73 | 12,300 | 205.78 k | 0 |
| 1 Jul 22 | William D. Turner | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 12.15 | 49,000 | 595.35 k | 0 |
| 1 Jul 22 | William D. Turner | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 12.05 | 75,000 | 903.75 k | 0 |